FAQs: 797 Pharmaceutical Compounding—Sterile Preparations
Last updated: August 29, 2017
General Chapter 797 was first published in 2004. The chapter was last revised in USP31–NF26 2nd Supplement, which became official on June 1, 2008.
A revision to General Chapter 797 was proposed for public comment from Sept. 25, 2015, to Jan. 31, 2016. Based on the nature and significance of the public comments received, the chapter will be revised and is anticipated to be published in the Pharmacopeial Forum 44(5) Sept./Oct. 2018 for a second round of public comment.
The revision to 797 will be harmonized with USP General Chapter 800 , with an anticipated official date of December 2019.
The revised chapter is anticipated to be published in the Pharmacopeial Forum 44(5) Sept./Oct. 2018 for a second round of public comment.
The public comment period is anticipated to be from September 4, 2018 to November 30, 2018.
The revised USP General Chapter 797 is expected to be published in USP 42-NF 37 Second Supplement on June 1, 2019 and become official on December 1, 2019. Sections of the revised 797 may have longer implementation dates that will allow time for adoption of the standard.
Sign up for USP Updates to receive notifications for USP General Chapter 797 revisions and other Healthcare Quality Safety standard.
While USP General Chapter 797 is undergoing revision, the published version of the chapter which became official on June 1, 2008 is currently official and enforceable.
You may purchase a copy of the currently official chapter through several publications. You may purchase the chapter through a subscription to the USP Compounding Compendium or USP-NF.
No, there is no conflict between these two guidance documents. General Chapter 797 references ISO 14644-1 to define the ISO classification of particulate matter in the primary and secondary engineering control. Additionally, the chapter specifies certification of engineering controls following procedures “such as those outlined in Certification Guide for Sterile Compounding Facilities (CAG-003-2006).” USP 797 further references CAG-002-2006 section 2.09 as sample procedures for placing Compounding Aseptic Isolators (CAI) and Compounding Aseptic Containment Isolators (CACI) outside of an ISO Class 7 buffer area. CAG-002-2006 section 2.09 is specifically referenced because it defines tests that prove whether a CAI or CACI can be placed outside of an ISO classified room. The test procedures in CAG-002-2006 are more robust than ISO 14644-1 because the tests increase the background particulate count. Section 2.09 increases background levels to prove that particulate contamination from the room is not dragged into the CAI or CACI when materials are transferred into or removed from the isolator. The procedures in ISO 14644-1 are not relevant to CAG-002-2006 section 2.09, and thus specific test procedures outlined in ISO 14644-1 are not referenced in these sections. Consequently, there is no conflict between CAG-002-2006 section 2.09 and ISO 14644-1.